> On Friday the FDA told Pfizer and Sanofi-Aventis that it would need an additional three months to study its inhaled insulin Exubera. An FDA advisory panel recommended approval last month. Report
> The FDA has approved a new version of the HIV drug Kaletra from Abbott Laboratories. Report
> Bristol-Myers Squibb and ImClone Systems have won a priority review for Erbitux as a treatment for head and neck cancer. Erbitux is approved as a therapy for colon cancer. Article
> A late-stage trial of Cimzia shows that a single injection was effective in controlling the signs and symptoms of Crohn's disease. Release
> AstraZeneca's Zactima has won orphan drug status for certain types of thyroid cancer. Report
> Sanofi-Pasteur has licensed a vaccine booster from Eisai. Article
> The FDA has accepted the supplemental BLA from Biogen and Elan for Rituxan for patients with active rheumatoid arthritis who inadequately respond to anti-TNF therapy. Release
> CytoKinetics has lined up $75 million in equity financing. Release
> The FDA has approved GlaxoSmithKline's Arranon for patients with particular types of leukemia and lymphoma. Release
> Invitrogen has struck a research partnership with China's drug screening center. Report
> PharmaFrontiers has received a green light from the FDA for a Phase IIb study of Tovaxin for MS. Release
> Am-Pharma of The Netherlands has lined up new financing. Release
And Finally… Mars is rolling out a new line of chocolate bars that it says are good for your health. Article